Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1933 1
1952 2
1954 1
1964 1
1967 3
1968 2
1969 2
1970 1
1971 2
1975 1
1976 1
1978 1
1979 2
1982 1
1983 1
1988 2
1989 1
1990 2
1991 2
1992 4
1993 3
1994 5
1996 4
1997 2
1998 1
1999 3
2000 2
2001 3
2002 1
2003 2
2004 3
2006 2
2007 2
2008 5
2009 6
2010 12
2011 20
2012 17
2013 15
2014 15
2015 10
2016 3
2017 7
2018 4
2019 7
2020 7
2021 11
2022 8
2023 16
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

206 results

Results by year

Filters applied: . Clear all
Page 1
Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study.
Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, Rutherford N, Martin JM, Frydenberg M, Shakher R, Wong LM, Taubman K, Ting Lee S, Hsiao E, Roach P, Nottage M, Kirkwood I, Hayne D, Link E, Marusic P, Matera A, Herschtal A, Iravani A, Hicks RJ, Williams S, Murphy DG; proPSMA Study Group Collaborators. Hofman MS, et al. Among authors: link e. Lancet. 2020 Apr 11;395(10231):1208-1216. doi: 10.1016/S0140-6736(20)30314-7. Epub 2020 Mar 22. Lancet. 2020. PMID: 32209449 Clinical Trial.
Radiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in the breast (BIG 3-07/TROG 07.01): a randomised, factorial, multicentre, open-label, phase 3 study.
Chua BH, Link EK, Kunkler IH, Whelan TJ, Westenberg AH, Gruber G, Bryant G, Ahern V, Purohit K, Graham PH, Akra M, McArdle O, O'Brien P, Harvey JA, Kirkove C, Maduro JH, Campbell ID, Delaney GP, Martin JD, Vu TTT, Muanza TM, Neal A, Olivotto IA; BIG 3–07/TROG 07.01 trial investigators. Chua BH, et al. Among authors: link ek. Lancet. 2022 Aug 6;400(10350):431-440. doi: 10.1016/S0140-6736(22)01246-6. Lancet. 2022. PMID: 35934006 Clinical Trial.
SLCO1B1 variants and statin-induced myopathy--a genomewide study.
SEARCH Collaborative Group; Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, Gut I, Lathrop M, Collins R. SEARCH Collaborative Group, et al. Among authors: link e. N Engl J Med. 2008 Aug 21;359(8):789-99. doi: 10.1056/NEJMoa0801936. Epub 2008 Jul 23. N Engl J Med. 2008. PMID: 18650507 Free article. Clinical Trial.
A Phase Ib/II Trial of Combined BRAF and EGFR Inhibition in BRAF V600E Positive Metastatic Colorectal Cancer and Other Cancers: The EVICT (Erlotinib and Vemurafenib In Combination Trial) Study.
Tan L, Tran B, Tie J, Markman B, Ananda S, Tebbutt NC, Michael M, Link E, Wong SQ, Chandrashekar S, Guinto J, Ritchie D, Koldej R, Solomon BJ, McArthur GA, Hicks RJ, Gibbs P, Dawson SJ, Desai J. Tan L, et al. Among authors: link e. Clin Cancer Res. 2023 Mar 14;29(6):1017-1030. doi: 10.1158/1078-0432.CCR-22-3094. Clin Cancer Res. 2023. PMID: 36638198 Free PMC article. Clinical Trial.
206 results